CN1633498A - 新型胰岛素/胰岛素样生长因子/松弛素家族多肽及其dna - Google Patents

新型胰岛素/胰岛素样生长因子/松弛素家族多肽及其dna Download PDF

Info

Publication number
CN1633498A
CN1633498A CNA018110762A CN01811076A CN1633498A CN 1633498 A CN1633498 A CN 1633498A CN A018110762 A CNA018110762 A CN A018110762A CN 01811076 A CN01811076 A CN 01811076A CN 1633498 A CN1633498 A CN 1633498A
Authority
CN
China
Prior art keywords
polypeptide
seq
dna
present
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018110762A
Other languages
English (en)
Chinese (zh)
Inventor
伊藤康明
铃木伸宏
西一纪
木泽秀树
原田征隆
大仪和宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CN1633498A publication Critical patent/CN1633498A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/64—Relaxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
CNA018110762A 2000-04-21 2001-04-20 新型胰岛素/胰岛素样生长因子/松弛素家族多肽及其dna Pending CN1633498A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP2000126340 2000-04-21
JP126340/2000 2000-04-21
JP2000205587 2000-07-03
JP205587/2000 2000-07-03
JP247962/2000 2000-08-10
JP2000247962 2000-08-10
JP395050/2000 2000-12-22
JP2000395050 2000-12-22

Publications (1)

Publication Number Publication Date
CN1633498A true CN1633498A (zh) 2005-06-29

Family

ID=27481250

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018110762A Pending CN1633498A (zh) 2000-04-21 2001-04-20 新型胰岛素/胰岛素样生长因子/松弛素家族多肽及其dna

Country Status (8)

Country Link
US (2) US7049403B2 (enExample)
EP (1) EP1283260A4 (enExample)
JP (1) JP4841054B2 (enExample)
KR (1) KR20020093053A (enExample)
CN (1) CN1633498A (enExample)
AU (2) AU4880901A (enExample)
CA (1) CA2406855A1 (enExample)
WO (1) WO2001081562A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116773828A (zh) * 2023-08-21 2023-09-19 成都大熊猫繁育研究基地 一种大熊猫rln3酶联免疫检测方法及单克隆抗体

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1317538A4 (en) * 2000-09-13 2005-04-06 Smithkline Beecham NOVEL CONNECTIONS
AUPR814401A0 (en) * 2001-10-08 2001-11-01 Howard Florey Institute Of Experimental Physiology And Medicine Human 3 relaxin
CA2517283A1 (en) * 2003-03-04 2004-09-30 Janssen Pharmaceutica N.V. Relaxin3-gpcr135 complexes and their production and use
WO2005075641A1 (ja) 2004-02-09 2005-08-18 Eisai R & D Management Co., Ltd. スクリーニング方法
EP1789452B1 (en) * 2004-08-25 2012-04-25 Janssen Pharmaceutica NV Relaxin-chimeric polypeptides and their preparation and use
ATE549351T1 (de) * 2007-01-30 2012-03-15 Janssen Pharmaceutica Nv Chimärer peptidantagonist für gpcr135 oder gpcr142
US9767495B2 (en) * 2008-12-19 2017-09-19 Sap Se Different sales and planning product options
US20100161366A1 (en) * 2008-12-19 2010-06-24 Achim Clemens Product requirement specification in production model

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2051375C (en) * 1989-05-04 2000-09-12 Dennis J. Henner Process and compositions for the isolation of human relaxin
AU9037898A (en) * 1997-09-24 1999-04-12 Genentech Inc. Insulin-like polypeptide and uses therefor
KR100448427B1 (ko) * 1998-10-13 2004-09-16 제넨테크, 인크. 신생 세포 성장을 억제하기 위한 방법 및 조성물
CA2347835A1 (en) 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU3228500A (en) * 1999-02-12 2000-08-29 Zymogenetics Inc. Insulin-family homolog localized to chromosome 1
EP1294887A1 (en) * 2000-03-10 2003-03-26 ZymoGenetics, Inc. Insulin homolog polypeptide zins4
US20020012967A1 (en) * 2000-03-10 2002-01-31 Holloway James L. Insulin homolog polypeptide zins4
EP1317538A4 (en) * 2000-09-13 2005-04-06 Smithkline Beecham NOVEL CONNECTIONS

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116773828A (zh) * 2023-08-21 2023-09-19 成都大熊猫繁育研究基地 一种大熊猫rln3酶联免疫检测方法及单克隆抗体
CN116773828B (zh) * 2023-08-21 2023-10-31 成都大熊猫繁育研究基地 一种大熊猫rln3酶联免疫检测方法及单克隆抗体
US12320817B2 (en) 2023-08-21 2025-06-03 Chengdu Research Base Of Giant Panda Breeding Enzyme-linked immunosorbent assay (ELISA) method and monoclonal antibody for giant panda relaxin-3 (RLN3)

Also Published As

Publication number Publication date
KR20020093053A (ko) 2002-12-12
EP1283260A1 (en) 2003-02-12
US7049403B2 (en) 2006-05-23
US20030158381A1 (en) 2003-08-21
AU2001248809B2 (en) 2005-05-19
WO2001081562A1 (en) 2001-11-01
AU4880901A (en) 2001-11-07
US7410641B2 (en) 2008-08-12
JP2002345468A (ja) 2002-12-03
CA2406855A1 (en) 2001-11-01
US20060073567A1 (en) 2006-04-06
EP1283260A4 (en) 2004-08-18
JP4841054B2 (ja) 2011-12-21

Similar Documents

Publication Publication Date Title
CN1324405A (zh) 新型g蛋白偶联型受体蛋白、dna及其配体
CN1310942C (zh) 校正基因
CN1149286C (zh) G蛋白偶联受体蛋白的配体多肽及其生产方法和用途
CN1134172A (zh) 原钙粘着蛋白蛋白质及其应用
CN1761680A (zh) 肿瘤迁移抑制素衍生物及其用途
CN1680441A (zh) 新型化合物
CN1894409A (zh) 人LXRα变体
CN1341123A (zh) 新型g蛋白偶联型受体蛋白及其dna
CN1328568A (zh) 肽衍生物
CN1633498A (zh) 新型胰岛素/胰岛素样生长因子/松弛素家族多肽及其dna
CN1333786A (zh) 新的g蛋白偶联型受体蛋白、其dna及其配体
CN1774634A (zh) 作用于酪氨酸激酶以诊断和治疗骨关节炎的方法和组合物
CN1747744A (zh) 使用otx2基因再生和新生视网膜感光细胞
CN1241940C (zh) 新型胶原蛋白样蛋白clac、其前体和它们的编码基因
CN1390256A (zh) 新型蛋白质及其dna
CN1359421A (zh) 新型多肽及其dna
WO2001044475A1 (fr) Nouveau polypeptide et son adn
CN1397019A (zh) 筛选方法
CN1324047C (zh) G蛋白偶联受体的配体与方法
CN1249087C (zh) 新的人g蛋白偶联受体
CN1961073A (zh) 切割型dance、dance复合体及其使用方法
CN101039956A (zh) 细胞表面糖蛋白
CN1809588A (zh) 调节骨相关活性的新方法
CN1154735C (zh) 哺乳动物的特洛德样基因和蛋白质
CN1155616C (zh) 具有促进癌细胞生长功能的新的人蛋白及其编码序列

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication